Sign Up to like & get
recommendations!
0
Published in 2021 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-21-0793
Abstract: Purpose: Standard-dose pembrolizumab plus alternative-dose ipilimumab (1 mg/kg Q3W for 4 doses) were tolerable and had robust antitumor activity in advanced melanoma in cohort B of the phase 1 KEYNOTE-029 study. Cohort C evaluated standard-dose…
read more here.
Keywords:
pem200 ipi50;
standard dose;
ipilimumab;
pembrolizumab plus ... See more keywords